SOUTH SAN FRANCISCO, Calif.,
Dec. 5, 2013 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced
that Raul R. Rodriguez, the
company's president and chief operations officer, is scheduled to
present a company overview at the Oppenheimer 24th
Annual Healthcare Conference in New York
City on Wednesday, December
11th at 2:10 p.m. ET.
To access the live audio webcast or the subsequent archived
recording, log on to www.rigel.com. Please connect to Rigel's
website several minutes prior to the start of the live webcast to
ensure adequate time for any software download that may be
necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage drug
development company that discovers and develops novel,
small-molecule drugs for the treatment of inflammatory and
autoimmune diseases, as well as muscle disorders. Rigel's
pioneering research focuses on intracellular signaling pathways and
related targets that are critical to disease mechanisms. The
Company currently has five product candidates in development:
fostamatinib, an oral SYK inhibitor for ITP expected to enter Phase
3 clinical trials in the first half of 2014; R348, a topical
JAK/SYK inhibitor for dry eye currently in Phase 2 clinical trials;
R118, an AMPK activator entering Phase 1 in early 2014; and two
oncology product candidates in Phase 1 development with partners
BerGenBio and Daiichi Sankyo.
Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com
SOURCE Rigel Pharmaceuticals, Inc.